AI Insight
This commentary discusses efinopegdutide as a potential therapeutic advance for metabolic dysfunction-associated steatohepatitis (MASH). MASH cirrhosis has emerged as a leading cause of liver transplantation and hepatocellular carcinoma globally. Advanced MASH fibrosis significantly increases all-cause mortality and nearly doubles the risk of cancers outside the liver.
Why it matters
The rising prevalence of MASH as a major driver of liver disease and cancer underscores the urgent need for effective treatments. New therapeutic options like efinopegdutide could address a significant gap in managing this growing health burden across diverse populations.
Understand the Science
The global impact of metabolic dysfunction-associated steatohepatitis (MASH) across diverse populations is significant. MASH cirrhosis has become a leading indication for liver transplantation and a primary driver of hepatocellular carcinoma. Advanced MASH fibrosis is associated with increased all-cause mortality and a nearly two-times increased risk of extrahepatic malignancies.1
Source: [Comment] Efinopegdutide: a step towards precision in MASH therapy?